SCHEMBL528127

SCHEMBL528127

CCC(CCc1ccccc1S)CNC(=O)C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.42
MTNR1A P48039 4/20 0.41
MTNR1B P49286 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
EPHX2 P34913 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 4/20 0.40
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
THRB P10828 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL528740 0.78 NAMPT (0.53) MTNR1AMTNR1BSMN1; SMN2NPC1PKM
SCHEMBL21682750 0.77 NAMPT (0.55) HPGDMTNR1AMTNR1BSMN1; SMN2NPC1
SCHEMBL27586031 0.76 NAAA (0.53) SMN1; SMN2RAB9AALDH1A1POLBTSHR
SCHEMBL12512483 0.70 USP2 (0.50) HPGDMTNR1AMTNR1BKMT2AALDH1A1
SCHEMBL6780014 0.68 LMNA (0.48) HPGDSMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL28342466 0.67 TP53 (0.49) SMN1; SMN2KMT2AALDH1A1MEN1KDM4E
SCHEMBL2795464 0.65 MTNR1A (0.59) HPGDMTNR1AMTNR1BSMN1; SMN2NPC1
SCHEMBL9131349 0.65 MTNR1A (0.69) MTNR1AMTNR1B
SCHEMBL8300495 0.65 KMT2A (0.65) HPGDSMN1; SMN2KMT2AALDH1A1KDM4E
SCHEMBL5610069 0.64 EPHX1 (0.58) SMN1; SMN2KMT2AALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3833336-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) 2021-06-16 EP claimed
WO-2020030814-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2020-02-13 WO claimed
EP-3833336-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) 2021-06-16 EP disclosed
WO-2020030814-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2020-02-13 WO disclosed
EP-2598158-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX Institut de Cardiologie de Montréal (CA) 2013-06-05 EP disclosed
WO-2012012870-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) 2012-02-02 WO disclosed